Visit COVID-19 resources

[Skip to Content]

A 12-month prospective study to evaluate the efficacy of using the treat-and-extend regimen with intravitreal aflibercept as a Second-Line Treatment for Diabetic Macular Oedema (the TADI Study) – (Eye Journal)

29 April 2020

This news item is available to RCOphth members only, please log in below to access.

Members Login